Obermatt

GC Biopharma

KSC:006280 · KR7006280002
BiotechnologySmall

360

52
Profit price95
Owner Earnings Yield1
Dividend Yield75
Price/Sales73
EV / Gross Profit90
Price/Book69
Return on Capital81
Cash Return on Capital89
Return on Equity87
EBIT Margin61
Gross Profitability62
Accruals40
Owner Earnings Margin85
Sales growth12
Profit Growth70
Long-Term EPS Growth51
Reinvestment42
Price momentum47
Debt load22
Refinancing86
Debt Payback1
Liquidity34
Analyst ratings62
Opinion Changes50
Price Target Upside33
Market mood69
Value Creation8/20creating some value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

GC Biopharma clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Profile

CountrySouth Korea
IndustryBiotechnology
SizeSmall
TypePublic Company
ExchangeKOSE
Employees313
ISINKR7006280002
Last UpdateApr 2, 2026
Themes
HematologyPain ManagementImmunologyInfectious DiseasesInflammationBiotechnologyHealth CarePharmaceutical

Description

Analysis

Quality compounder

GC Biopharma Corp. is a quality compounder: a well-run business trading at a price that reflects what it is worth.

Valuation data is not available for this company.

The trajectory is moderate and the balance sheet is stretched. The company scores 8/20 on our value-creation score: creating some value.

Nothing is flagged here: no red or amber gates, no divergence between profits and cash. That is itself information: the numbers are straightforward. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
68
2026

All-time high

75

Mar 2026

All-time low

68

Jun 2026

Average rank

72

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
73
Price/Earnings
82
Price/Book
69
Dividend Yield
75
Value (overall)
100

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare GC Biopharma with its peers
JW Pharmaceutical
KSC:001060
95
CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Green Cross
KSC:005250
28
CountrySouth Korea
IndustryBiotechnology
SizeMedium
Full Stock Analysis →
Handok
KSC:002390
15
CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Chong Kun Dang
KSC:185750
55
CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Hanmi Pharmaceutical
KSC:128940
76
CountrySouth Korea
IndustryPharmaceuticals
SizeMedium
Full Stock Analysis →
Dong-A ST
KSC:170900
39
CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →